Market research
PTX.AU Prescient Therapeutics Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 80M
- P/E ratio
- Not available
- Analyst target
- 0.135
- Dividend yield
- Not available
- Beta
- 0.77
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000PTX3
- Market cap
- 80M
- P/E ratio
- Not available
- Analyst target
- 0.135
- Dividend yield
- Not available
- Beta
- 0.77
About
About Prescient Therapeutics Limited
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first-in-class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company is also developing cell therapy platforms, including CellPryme, a high-performance cell therapy enhancement platform; and OmniCAR, is a platform seeks to overcome the challenges of conventional CAR-T therapy including manufacturing, safety and reliability. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PTX.AU discussion.
5 years, 5 months ago
Prescient Therapeutics Limited is currently in a long term uptrend where the price is trading 148.8% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Prescient Therapeutics Limited's total revenue sank by 8.6% to $38K since the same quarter in the previous year.
Its net income has dropped by 6.0% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 270.8% to $-793K since the same quarter in the previous year.
Based on the above factors, Prescient Therapeutics Limited gets an overall score of 2/5.